587 related articles for article (PubMed ID: 33751787)
1. Safety of fibrates in cholestatic liver diseases.
Carrion AF; Lindor KD; Levy C
Liver Int; 2021 Jun; 41(6):1335-1343. PubMed ID: 33751787
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis.
Zhang H; Li S; Feng Y; Zhang Q; Xie B
Clin Exp Med; 2023 Sep; 23(5):1741-1749. PubMed ID: 36318376
[TBL] [Abstract][Full Text] [Related]
3. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Khakoo NS; Sultan S; Reynolds JM; Levy C
Dig Dis Sci; 2023 Apr; 68(4):1559-1573. PubMed ID: 36180756
[TBL] [Abstract][Full Text] [Related]
5. Fibrates for Primary Biliary Cholangitis: What's All the Hype?
Levy C
Ann Hepatol; 2017; 16(5):704-706. PubMed ID: 28809729
[TBL] [Abstract][Full Text] [Related]
6. Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis.
Shen N; Pan J; Miao H; Zhang H; Xing L; Yu X
Ann Palliat Med; 2021 Jul; 10(7):7697-7705. PubMed ID: 34353058
[TBL] [Abstract][Full Text] [Related]
7. [Autoimmune mediated cholestatic liver diseases].
Mayer LS; Käser R; Böttler T
Dtsch Med Wochenschr; 2020 Mar; 145(5):296-305. PubMed ID: 32120404
[TBL] [Abstract][Full Text] [Related]
8. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
[TBL] [Abstract][Full Text] [Related]
9. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.
Wang C; Shi Y; Wang X; Ma H; Liu Q; Gao Y; Niu J
Front Immunol; 2022; 13():940688. PubMed ID: 35880178
[TBL] [Abstract][Full Text] [Related]
11. Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review.
Suraweera D; Rahal H; Jimenez M; Viramontes M; Choi G; Saab S
Liver Int; 2017 Dec; 37(12):1877-1886. PubMed ID: 28517369
[TBL] [Abstract][Full Text] [Related]
12. Editorial: Itching to Know: Role of Fibrates in PBC.
Levy C; Lindor KD
Am J Gastroenterol; 2018 Jan; 113(1):56-57. PubMed ID: 29311728
[TBL] [Abstract][Full Text] [Related]
13. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
[TBL] [Abstract][Full Text] [Related]
14. Additional fibrate treatment in UDCA-refractory PBC patients.
Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
[TBL] [Abstract][Full Text] [Related]
15. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population.
Cançado GGL; Braga MH; Ferraz MLG; Villela-Nogueira CA; Terrabuio DRB; Cançado ELR; Nardelli MJ; Faria LC; Gomes NMF; de Oliveira EMG; Rotman V; de Oliveira MB; da Cunha SMCF; Mazo DFC; Mendes LSC; Ivantes CAP; Codes L; de Almeida E Borges VF; Pace FHL; Pessoa MG; Signorelli IV; Coral GP; Bittencourt PL; Levy C; Couto CA;
Ann Hepatol; 2022; 27(1):100546. PubMed ID: 34600142
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Primary Biliary Cholangitis including Transplantation.
Muzahim Y; Wakil A; Bassi M; Pyrsopoulos N
Clin Liver Dis; 2024 Feb; 28(1):103-114. PubMed ID: 37945152
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Dohmen K; Tanaka H; Haruno M
Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
[TBL] [Abstract][Full Text] [Related]
20. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.
Bolier R; de Vries ES; Parés A; Helder J; Kemper EM; Zwinderman K; Elferink RPO; Beuers U;
Trials; 2017 May; 18(1):230. PubMed ID: 28535810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]